Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 14,337 shares, an increase of 85.2% from the April 30th total of 7,742 shares. Based on an average daily trading volume, of 20,059 shares, the short-interest ratio is presently 0.7 days. Currently, 0.0% of the company’s shares are sold short.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Baird Financial Group Inc. lifted its stake in Barinthus Biotherapeutics by 108.2% in the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after acquiring an additional 100,000 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Barinthus Biotherapeutics by 115.8% in the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after purchasing an additional 76,800 shares in the last quarter. Finally, Rangeley Capital LLC boosted its holdings in Barinthus Biotherapeutics by 88.8% during the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after purchasing an additional 75,024 shares during the last quarter. 25.20% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.00.

Barinthus Biotherapeutics Stock Performance

BRNS stock traded up $0.00 during mid-day trading on Wednesday, hitting $0.66. 850 shares of the company were exchanged, compared to its average volume of 35,521. Barinthus Biotherapeutics has a 1-year low of $0.51 and a 1-year high of $2.92. The firm’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.67. The firm has a market cap of $27.12 million, a P/E ratio of -0.51 and a beta of -0.40.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.14.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.